Compares other immunotherapy, has the low toxicity, the price is cheap, is suitable for characteristics and so on all cancers
2 Phase of clinical trials displayed, 2 patients in accept treat in the latter 4-5 year the brain tumor to eliminate completely
Slow Virus Carrier Technology
1st enters based on the slow viral carrier technology's vaccine to the clinical trial, the anticancer treatment vaccine, the infectious disease vaccine. Non-copying, the conformity, the non-pathogenicity, the immunity affects strong, the duration long and the indication is broad. manufacture flow:
Synthesized New Epi-Position Cancer Vaccine PYI
Indication: Lung cancer/ovarian cancer/colon cancer/breast cancer synthesized 10 antigen new epi-positions, target to 5 kind of tumor relevant antigen. In the patient the position lifetime his match enhances for 12.3 months compared to many west, 1 year survival rate enhances 26%.
Corporation and many domestic well-known colleges and universities and factory establishment strategy cooperation. Corporation and more than 100 factory establishment friendly cooperative relationship.
SUBSCRIBE TO EMAIL
Fukang kernel carries out “ The absolute sincerity service, the science innovate ” The faith, the absolute sincerity cooperation, dares to innovate. The present Fukang kernel is being at the high speed development phase, invites steadfast, to have the innovative spirit outstanding talent diligently honestly to join us.